Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Apoteket omstrukturering AB in connection with the sale of pharmacies
Mandate

Vinge has advised Apoteket omstrukturering AB in connection with the sale of pharmacies

November 10, 2009

Vinge has advised Apoteket Omstrukturering AB in connection with the reregulation of the Swedish pharmacy market and in connection with the disposal through Apoteket AB (publ) of 8 so-called cluster companies consisting of a total of 465 pharmacies to Kronans Droghandel/KF, Altor, Priveq/Investor Growth Capital and Segulah for a total purchase price of approximately SEK 5.9 billion.

The Vinge team was led by Carl Gustaf De Geer and Henrik Wenckert and included associates from different practice areas such as M&A, Banking & Finance, EU &Antitrust, IT/Telecom, Employment & Benefits, Real Estate, Intellectual Property and also entailed regulatory issues regarding the pharmaceuticals legislation including licensing on the pharmacy market.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026